These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 11520837)
1. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. Gilbert RE; Augood C; Gupta R; Ades AE; Logan S; Sculpher M; van Der Meulen JH BMJ; 2001 Aug; 323(7310):423-5. PubMed ID: 11520837 [TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic. Dhaifalah I; Májek O Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640 [TBL] [Abstract][Full Text] [Related]
5. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. Gekas J; Gagné G; Bujold E; Douillard D; Forest JC; Reinharz D; Rousseau F BMJ; 2009 Feb; 338():b138. PubMed ID: 19218323 [TBL] [Abstract][Full Text] [Related]
6. Importance of the integrated test in the Down's syndrome screening algorithm. Springer D; Loucky J; Tesner P; Cutka D; Stejskal D; Gregor V; Zima T J Med Screen; 2018 Sep; 25(3):114-118. PubMed ID: 29575979 [TBL] [Abstract][Full Text] [Related]
7. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. Wald NJ; Watt HC; Hackshaw AK N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601 [TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of prenatal screening strategies for Down syndrome. Odibo AO; Stamilio DM; Nelson DB; Sehdev HM; Macones GA Obstet Gynecol; 2005 Sep; 106(3):562-8. PubMed ID: 16135588 [TBL] [Abstract][Full Text] [Related]
10. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases. Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230 [TBL] [Abstract][Full Text] [Related]
11. Retrospective audit of different antenatal screening policies for Down's syndrome in eight district general hospitals in one health region. Wellesley D; Boyle T; Barber J; Howe DT BMJ; 2002 Jul; 325(7354):15. PubMed ID: 12098722 [TBL] [Abstract][Full Text] [Related]
12. Using decision analysis to compare policies for antenatal screening for Down's syndrome. Fletcher J; Hicks NR; Kay JD; Boyd PA BMJ; 1995 Aug; 311(7001):351-6. PubMed ID: 7640539 [TBL] [Abstract][Full Text] [Related]
13. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. Cheffins T; Chan A; Haan EA; Ranieri E; Ryall RG; Keane RJ; Byron-Scott R; Scott H; Gjerde EM; Nguyen AM; Ford JH; Sykes S BJOG; 2000 Dec; 107(12):1453-9. PubMed ID: 11192100 [TBL] [Abstract][Full Text] [Related]
14. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869 [TBL] [Abstract][Full Text] [Related]
15. Antenatal screening for Down's syndrome with the quadruple test. Wald NJ; Huttly WJ; Hackshaw AK Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052 [TBL] [Abstract][Full Text] [Related]
16. Second trimester screening for Down's syndrome: 7 years experience. Beaman JM; Goldie DJ J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551 [TBL] [Abstract][Full Text] [Related]
17. [Evaluation of a programme for the prenatal screening for Down's syndrome by ultrasonographic nuchal translucency measurement and serum determinations in the first trimester of pregnancy]. Go AT; Hupkes HW; Lomecky M; Twisk J; Blankenstein JM; van Vugt JM Ned Tijdschr Geneeskd; 2005 Dec; 149(50):2795-9. PubMed ID: 16385832 [TBL] [Abstract][Full Text] [Related]